European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis.

• 影响指数: 9.228
• 发表时间: Oct 2017
• 来源期刊: J Eur Acad Dermatol Venereol
• DOI: 10.1111/jdv.14466
• PMID: 28786499
• 文章类型: Journal Article
• 中科院分区: Q1
• 方向: 医学
• 作者列表: Knobler R,Moinzadeh P,Hunzelmann N,Kreuter A,Cozzio A,Mouthon L,Cutolo M,Rongioletti F,Denton CP,Rudnicka L,Frasin LA,Smith V,Gabrielli A,Aberer E,Bagot M,Bali G,Bouaziz J,Braae Olesen A,Foeldvari I,Frances C,Jalili A,Just U,Kähäri V,Kárpáti S,Kofoed K,Krasowska D,Olszewska M,Orteu C,Panelius J,Parodi A,Petit A,Quaglino P,Ranki A,Sanchez Schmidt JM,Seneschal J,Skrok A,Sticherling M,Sunderkötter C,Taieb A,Tanew A,Wolf P,Worm M,Wutte NJ,Krieg T

Mesh: Diagnosis, Differential; Humans; Nephrogenic Fibrosing Dermopathy / diagnosis pathology therapy; Scleredema Adultorum / diagnosis pathology therapy; Scleromyxedema / diagnosis pathology therapy

Abstract

The term \'sclerosing diseases of the skin\' comprises specific dermatological entities which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish from each other. The present guideline focuses on characteristic clinical and histopathological features, diagnostic scores and the serum autoantibodies most useful for differential diagnosis. In addition, current strategies in the first- and advanced-line therapy of sclerosing skin diseases are addressed in detail. Part 2 of this guideline provides clinicians with an overview of the diagnosis and treatment of scleromyxedema, scleredema (of Buschke) and nephrogenic systemic sclerosis (nephrogenic fibrosing dermopathy).